| Name | Title | Contact Details |
|---|
Cityblock was founded in 2017 as the first tech-driven provider for communities with complex needs. We deliver better care to where it`s needed most, investing upstream in highly personalized, prevention-oriented health and social care to ultimately drive down costs and improve outcomes. Our tech enables scale by bringing together practical information, coordination, and communication for our members and our care teams. We are adamant about building a radically better member experience for people living in lower-income neighborhoods that have never been prioritized.
Medical Management Strategies is a San Luis Obispo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Perimed is a North Royalton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interactive Health, the country’s leading provider of health management solutions, creates innovative wellness programs designed to increase overall company health and actively engage employees to make lasting behavior changes. For every company’s perspective on health management, early stage or mature, Interactive Health has a highly flexible program to meet its needs. By offering health evaluations that detect risk proactively, Interactive Health has the capability to immediately intervene and engage at-risk participants with a personalized course of action. Using ActiveEngine(TM), a proprietary algorithmic-based clinical intelligence engine, a unique achievable goal is assigned to each participant based on individual results and health improvements are measured. Interactive Health has a 20+ year track record of creating the Healthiest Companies in America.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.